Download PDF
Der Nuklearmediziner 2002; 25(4): 263-268
DOI: 10.1055/s-2002-36475
Skelettdiagnostik

© Georg Thieme Verlag Stuttgart · New York

Die Positronenemissionstomographie in der Diagnostik von Erkrankungen des Skelettsystems

PET in Skeletal DiseasesH. Schirrmeister1
  • 1Klinik für Nuklearmedizin der Christian-Albrechts-Universität zu Kiel
Further Information

Publication History

Publication Date:
07 January 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nach Vorstellung des ersten industriereifen Positronenemissionstomographen im Jahre 1975 stand zunächst die Untersuchung des Hirnstoffwechsels im Vordergrund der klinischen Forschung. Seit Ende der Achtzigerjahre kommt die PET auch zunehmend in der Kardiologie und Onkologie zur Anwendung. Seit der Mitte der Neunzigerjahre wird die PET auch zur Klärung orthopädischer Fragestellungen, beispielsweise bei der Diagnostik einer Osteomyelitis oder in der Vitalitätsdiagnostik von Knochentransplantaten eingesetzt. Die onkologische Skelettdiagnostik beinhaltet die Suche nach Skelettmetastasen und die Untersuchung der Aggressivität, dem Staging und der Therapiekontrolle primärer Knochentumoren. Im Folgenden werden die aus der Literatur bekannten Ergebnisse der Skelettdiagnostik mit PET vorgestellt und diskutiert.

Abstract

The first PET camera was introduced into clinical practice in 1975. Initially, PET was considered an excellent research modality for assessment of brain metabolism. Since the early 1980s numerous studies demonstrated its ability to answer questions in cardiology and oncology like detecting hibernating myocardium and differential diagnosis, staging and therapy control of several malignant tumors. Since the mid-1990s PET has also been used for orthopaedic indications such as assessment of osteomyelitis and viability control of bone crafts. Further applications in assessment of bone disorders are screening for bone metastases and staging and therapy control of primary bone tumors.

Schlüsselwörter

PET - Skelett - Fluordesoxyglukose - Natriumfluorid

Key words

PET - skeleton - fluorodeoxyglucose - sodium fluoride

Literatur

  • 1 Capanaci M. Bone and Soft Tissue Tumors. Springer, Wien, New York 1990
    Google Scholar
  • 2 Kern K A, Brunetti A, Norton J A, Chang A E, Malawer M, Lack E, Finn R D, Rosenberg S A, Larson S M. Metabolic imaging of human extremity musculoskeletal tumors by PET.  J Nucl Med. 1988;  29 181-186
    PubMedGoogle Scholar
  • 3 Adler L P, Blair H F, Markley J T, Wiliams R P, Joyce M J, Leisure G, al-Kaisi N, Miraldi F. Noninvasive Grading of musculoskeletal tumors using PET.  J Nucl Med. 1991;  32 1508-1512
    PubMedGoogle Scholar
  • 4 Dehdashti F, Siegel B A, Griffeth L K, Fuselman M J, Trask D D, McGuire A H, McGuire D J. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F18]fluoro-2-deoxyglucose.  Radiology. 1996;  200 243-247
    PubMedGoogle Scholar
  • 5 Kole A C, Nieweg O E, Hoekstra H J, van Horn J R, Koops H S, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors.  J Nucl Med. 1998;  39 810-815
    PubMedGoogle Scholar
  • 6 Schulte M, Brecht-Kraus D, Heymer B, Guhlmann A, Hartwig E, Sarkar M R, Diederichs C G, von Baer A, Kotzerke J, Reske S N. Grading of tumors and tumorlike of bone: evaluation by FDG-PET.  J Nucl Med. 2000;  41 1695-1701
    PubMedGoogle Scholar
  • 7 Franzius C, Daldrup-Link H E, Wagner-Bohn A, Sciuk J, Heindel W L, Jürgens H, Schober O. FDG-PET for detection of recurences from malignant primary bone tumors: comparison with conventional imaging.  Ann Oncol. 2002;  13 157-160
    CrossrefPubMedGoogle Scholar
  • 8 Meyers P A, Heller G, Healey J. et al . Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience.  J Clin Oncol. 1992;  10 5-15
    PubMedGoogle Scholar
  • 9 Schulte M, Brecht-Kraus D, Werner M. et al . Evaluation of neoadjuvant therapy response of osteogenic sarkoma using 2-[Fluorine-18]-Fluoro-2-Deoxy-2-Glucose.  J Nucl Med. 1999;  40 1637-1643
    PubMedGoogle Scholar
  • 10 Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.  Clin Nucl Med. 2000;  25 874-881
    CrossrefPubMedGoogle Scholar
  • 11 Rubens R D, Fogelman I. Bone Metastases. Springer, London, Berlin, Heidelberg, New York, Tokio, Honkong 1991
    Google Scholar
  • 12 Schirrmeister H, Guhlmann C A, Nüssle K, Elsner K, Kotzerke J, Reske S N. Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung von Skelettmetastasen.  Röntgenpraxis. 1999;  52 19-25
    PubMedGoogle Scholar
  • 13 Schirrmeister H, Buck A K, Guhlmann C A, Reske S N. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with 18F-sodium fluoride PET.  Thyroid. 2001;  11 677-683
    CrossrefPubMedGoogle Scholar
  • 14 Venz S, Hosten N, Friedrichs R, Neumann K, Nagel R, Felix R. Osteoplastische Knochenmetastasen beim Prostatakarzinom: Magnetresonanztomographie und Knochenmarkszintigraphie.  Fortschr Röntgenstr. 1994;  161 64-69
    PubMedGoogle Scholar
  • 15 Gosfield E, Alavi A, Kneeland B. Comparison of Radionuclide Bone Scans and Magnetic Resonance Imaging in Detecting Spinal Metastases.  J Nucl Med. 1993;  34 2191-2198
    PubMedGoogle Scholar
  • 16 Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, Neumaier B, Nüssle K, Reske S N. Sensitivity in detecting osseous lesions depends on anatomical localization: Planar bone scintigraphy vs. 18F-PET.  J Nucl Med. 1999;  40 1623-1629
    PubMedGoogle Scholar
  • 17 Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Glatting G, Träger H, Neumaier B, Reske S N. Early detection and accurate description of extent of metastatic bone disease in breast cancer with 18F-fluoride ion and positron emission tomography.  J Clin Oncol. 1999;  17 2381-2389
    PubMedGoogle Scholar
  • 18 Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck A K, Dziuk K, Gabelmann A, Reske S N, Hetzel M. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer.  J Nucl Med. 2001;  42 1800-1804
    PubMedGoogle Scholar
  • 19 Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo B. Fluorine-18 deoxyglucose positron emission tomography for detection of bone metastases in patients with non-small cell lung cancer.  Eur J Nucl Med. 1998;  25 1244-1247
    CrossrefPubMedGoogle Scholar
  • 20 Cook G J, Houston S, Rubens R D, Maisey M N, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.  J Clin Oncol. 1998;  16 3375-3379
    PubMedGoogle Scholar
  • 21 Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, Koretz K, Glatting G, Rieber A, Kreienberg R, Buck A, Reske S N. [F-18] 2-deoxy-2-fluoro D-glucose PET in preoperative staging of breast cancer - Comparison with the standard staging procedures.  Eur J Nucl Med. 2001;  28 351-358
    CrossrefPubMedGoogle Scholar
  • 22 Shreve P D, Grossmann H B, Gross M D, Wahl R L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro D-glucose.  Radiology. 1996;  199 751-756
    CrossrefPubMedGoogle Scholar
  • 23 Franzius C, Sciuk J, Daldrup-Link H E, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors with bone scintigraphy.  Eur J Nucl Med. 2000;  27 1305-1311
    CrossrefPubMedGoogle Scholar
  • 24 Hoane B R, Shields A F, Porter B A. et al . Detection of lymphomateous bone marrow involvement with magnetic resonance imaging.  Blood. 1991;  78 728-738
    PubMedGoogle Scholar
  • 25 Shields A F, Porter B A, Churchley S. et al . The detection of bone marrow involvement by lymphoma using magnetic resonance imaging.  J Clin Oncol. 1987;  5 225-230
    PubMedGoogle Scholar
  • 26 Lecouvet F E, Malghem J, Michaux L, Maldague B, Ferrant A. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey.  Br J Haemtol. 1999;  106 35-39
    CrossrefPubMedGoogle Scholar
  • 27 Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhoven N, Reske S N. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomateous bone marrow.  J Clin Oncol. 1998;  16 603-609
    PubMedGoogle Scholar
  • 28 Moog F, Kotzerke J, Reske S N. FDG-PET can replace bone scintigraphy in primary staging of malignant lymphoma.  J Nucl Med. 1999;  40 1407-1413
    PubMedGoogle Scholar
  • 29 Carr R, Barrington S F, Madan B, O'Doherty M R, Saunders C A, van der Walt J, Timothy A R. Detection of lymphoma in bone marrow by whole-body positron emission tomography.  Blood. 1998;  91 3340-3346
    PubMedGoogle Scholar
  • 30 Schirrmeister H, Bommer M, Buck A K, Müller S, Messer P, Bunjes D, Bergmann L, Reske S N. Initial results in assessment of multiple myeloma by using F-18 FDG and positron emission tomography.  Eur J Nucl Med. 2002;  29 361-366
    CrossrefPubMedGoogle Scholar
  • 31 Guhlmann A, Brecht-Kraus D, Suger G, Glatting G, Kotzerke J, Kinzl L, Reske S N. Fluorine-18 FDG PET and technetium-99m atigranulzyte antibody scintigraphy in chronic osteomyelitis.  J Nucl Med. 1998;  39 2145-2152
    PubMedGoogle Scholar
  • 32 Guhlmann A, Brecht-Kraus D, Suger G, Glatting G, Kotzerke J, Kinzl L, Reske S N. Chronic Osteomyelitis: detection with FDG PET and correlation with histopathologic findings.  Radiology. 1998;  206 749-754
    CrossrefPubMedGoogle Scholar
  • 33 Berding G, Burchert W, van den Hoff J, Pytlik C, Neukam F W, Meyer G J, Gratz K F, Hundeshagen H. Evaluation of the incorporation of bone grafts using in maxillofacial surgery with [18F]-fluoride ion and dynamic positron emission tomography.  Eur J Nucl Med. 1995;  22 1133-1140
    PubMedGoogle Scholar
  • 34 Schiepers C, Nuyts J, Bormans G, Dequeker J, Bouillon R, Mortelmanns L, De Roo M. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET.  J Nucl Med. 1997;  38 1970-1976
    PubMedGoogle Scholar
  • 35 Schiepers C, Broos P, Miserez M, Bormans G, De Roo M. Measeurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis.  Arch Orthop Trauma Surg. 1998;  118 131-135
    PubMedGoogle Scholar

Dr. med. Holger Schirrmeister

Christian-Albrechts- Universität zu Kiel · Klinik für Nuklearmedizin

Arnold-Heller-Straße 9

24105 Kiel

Email: hschirrmeister@wkk-hei.de